Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study

Detalhes bibliográficos
Autor(a) principal: Zanella, Maria Teresa [UNIFESP]
Data de Publicação: 2006
Outros Autores: Uehara, Marcelo Hiroshi [UNIFESP], Ribeiro, Artur Beltrame [UNIFESP], Bertolami, Marcelo, Falsetti, Ana Claudia, Yunes, Mirela A.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1590/S0004-27302006000200023
http://repositorio.unifesp.br/handle/11600/3047
Resumo: Weight loss improves metabolic abnormalities and reduces cardiovascular risk in obese hypertensive patients. To evaluate the impact of a sustained weight loss on coronary risk, 181 hypertensive patients with metabolic syndrome underwent to orlistat therapy, 120 mg, t.i.d., plus diet for 36 weeks. During therapy, Framingham risk scores (FRS) were calculated for determination of coronary heart disease risk in ten years. Body mass index decreased from 35.0 ± 4.2 to 32.6 ± 4.5 kg/m² (p< 0.0001) and waist circumference from 108.1 ± 10.1 to 100.5 ± 11.1 cm (p< 0.0001), at the end of the study period (week 36). Systolic and diastolic blood pressure showed reductions after the two first weeks, which were maintained up to the end of the study. A clear shift to the left in FRS distribution curve occurred at the end of the study, compared to baseline, indicating a reduction in coronary risk. Over all patients at risk, 49.2% moved to a lower risk category. A weight loss > 5% occurred in 64.6% of all patients, associated with improvement in glucose metabolism. Among those with abnormal glucose metabolism, 38 out 53 patients (71.7%) improved their glucose tolerance (p< 0.0005). In conclusion, long-term orlistat therapy helps to reduce and maintain a lower body weight, decreasing risk of coronary disease and improving glucose metabolism, thus protecting against type 2 diabetes.
id UFSP_f96504a25fb9f717a8803a6310fd9580
oai_identifier_str oai:repositorio.unifesp.br/:11600/3047
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS studyAvaliação do risco cardiovascular em pacientes obesos hipertensos com síndrome metabólica: estudo ARCOSCentral obesityOrlistatWeight reductionCardiovascular riskFramingham risk scoreObesidade centralOrlistatRedução de pesoRisco cardiovascularScore de risco de FraminghamWeight loss improves metabolic abnormalities and reduces cardiovascular risk in obese hypertensive patients. To evaluate the impact of a sustained weight loss on coronary risk, 181 hypertensive patients with metabolic syndrome underwent to orlistat therapy, 120 mg, t.i.d., plus diet for 36 weeks. During therapy, Framingham risk scores (FRS) were calculated for determination of coronary heart disease risk in ten years. Body mass index decreased from 35.0 ± 4.2 to 32.6 ± 4.5 kg/m² (p< 0.0001) and waist circumference from 108.1 ± 10.1 to 100.5 ± 11.1 cm (p< 0.0001), at the end of the study period (week 36). Systolic and diastolic blood pressure showed reductions after the two first weeks, which were maintained up to the end of the study. A clear shift to the left in FRS distribution curve occurred at the end of the study, compared to baseline, indicating a reduction in coronary risk. Over all patients at risk, 49.2% moved to a lower risk category. A weight loss > 5% occurred in 64.6% of all patients, associated with improvement in glucose metabolism. Among those with abnormal glucose metabolism, 38 out 53 patients (71.7%) improved their glucose tolerance (p< 0.0005). In conclusion, long-term orlistat therapy helps to reduce and maintain a lower body weight, decreasing risk of coronary disease and improving glucose metabolism, thus protecting against type 2 diabetes.A perda de peso melhora as anormalidades metabólicas e reduz o risco cardiovascular em pacientes obesos hipertensos. Com o objetivo de avaliar o impacto da perda de peso mantida sobre o risco coronariano, submetemos 181 pacientes hipertensos com síndrome metabólica à terapia com orlistat, 120 mg, três vezes ao dia, mais dieta, por um período de 36 semanas. Durante a terapia, foram calculados os scores de risco de Framingham (FRS) para a determinação do risco de doença cardíaca coronariana em dez anos. Ao final do período de estudo (semana 36), o índice de massa corpóreo diminuiu de 35,0 ± 4,2 para 32,6 ± 4,5 kg/m² (p< 0,0001) e a circunferência da cintura de 108,1 ± 10,1 para 100,5 ± 11,1 cm (p< 0,0001). As pressões sistólica e diastólica mostraram reduções após as primeiras duas semanas, que se mantiveram até o final do estudo. Um deslocamento evidente para a esquerda na curva de distribuição do FRS ocorreu no final do estudo, em comparação com os valores basais, indicando redução no risco coronariano. Do total de pacientes em risco, 49,2% passou para uma categoria de risco menor. Ocorreu perda de peso > 5% em 64,6% de todos os pacientes, associada com melhora no metabolismo da glicose. Entre os 53 pacientes com metabolismo de glicose anormal, 38 (71,7%) melhoraram sua tolerância à glicose (p< 0,0005). Em conclusão, terapia de longa duração com orlistat auxilia a reduzir e manter mais baixo o peso corpóreo, reduzindo o risco de doença coronária e melhorando o metabolismo da glicose e protegendo, dessa maneira, contra o diabetes tipo 2.Federal University of São Paulo Divisions of EndocrinologyFederal University of São Paulo Division of NephrologyInstituto Dante Pazzaneze de Cardiologia Service of CardiologyRoche LaboratoriesUNIFESP, Divisions of EndocrinologyUNIFESP, Division of NephrologySciELOSociedade Brasileira de Endocrinologia e MetabologiaUniversidade Federal de São Paulo (UNIFESP)Instituto Dante Pazzaneze de Cardiologia Service of CardiologyRoche LaboratoriesZanella, Maria Teresa [UNIFESP]Uehara, Marcelo Hiroshi [UNIFESP]Ribeiro, Artur Beltrame [UNIFESP]Bertolami, MarceloFalsetti, Ana ClaudiaYunes, Mirela A.2015-06-14T13:32:05Z2015-06-14T13:32:05Z2006-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion368-376application/pdfhttp://dx.doi.org/10.1590/S0004-27302006000200023Arquivos Brasileiros de Endocrinologia & Metabologia. Sociedade Brasileira de Endocrinologia e Metabologia, v. 50, n. 2, p. 368-376, 2006.10.1590/S0004-27302006000200023S0004-27302006000200023.pdf0004-2730S0004-27302006000200023http://repositorio.unifesp.br/handle/11600/3047engArquivos Brasileiros de Endocrinologia & Metabologiainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-04T21:22:10Zoai:repositorio.unifesp.br/:11600/3047Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-04T21:22:10Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study
Avaliação do risco cardiovascular em pacientes obesos hipertensos com síndrome metabólica: estudo ARCOS
title Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study
spellingShingle Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study
Zanella, Maria Teresa [UNIFESP]
Central obesity
Orlistat
Weight reduction
Cardiovascular risk
Framingham risk score
Obesidade central
Orlistat
Redução de peso
Risco cardiovascular
Score de risco de Framingham
title_short Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study
title_full Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study
title_fullStr Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study
title_full_unstemmed Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study
title_sort Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study
author Zanella, Maria Teresa [UNIFESP]
author_facet Zanella, Maria Teresa [UNIFESP]
Uehara, Marcelo Hiroshi [UNIFESP]
Ribeiro, Artur Beltrame [UNIFESP]
Bertolami, Marcelo
Falsetti, Ana Claudia
Yunes, Mirela A.
author_role author
author2 Uehara, Marcelo Hiroshi [UNIFESP]
Ribeiro, Artur Beltrame [UNIFESP]
Bertolami, Marcelo
Falsetti, Ana Claudia
Yunes, Mirela A.
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
Instituto Dante Pazzaneze de Cardiologia Service of Cardiology
Roche Laboratories
dc.contributor.author.fl_str_mv Zanella, Maria Teresa [UNIFESP]
Uehara, Marcelo Hiroshi [UNIFESP]
Ribeiro, Artur Beltrame [UNIFESP]
Bertolami, Marcelo
Falsetti, Ana Claudia
Yunes, Mirela A.
dc.subject.por.fl_str_mv Central obesity
Orlistat
Weight reduction
Cardiovascular risk
Framingham risk score
Obesidade central
Orlistat
Redução de peso
Risco cardiovascular
Score de risco de Framingham
topic Central obesity
Orlistat
Weight reduction
Cardiovascular risk
Framingham risk score
Obesidade central
Orlistat
Redução de peso
Risco cardiovascular
Score de risco de Framingham
description Weight loss improves metabolic abnormalities and reduces cardiovascular risk in obese hypertensive patients. To evaluate the impact of a sustained weight loss on coronary risk, 181 hypertensive patients with metabolic syndrome underwent to orlistat therapy, 120 mg, t.i.d., plus diet for 36 weeks. During therapy, Framingham risk scores (FRS) were calculated for determination of coronary heart disease risk in ten years. Body mass index decreased from 35.0 ± 4.2 to 32.6 ± 4.5 kg/m² (p< 0.0001) and waist circumference from 108.1 ± 10.1 to 100.5 ± 11.1 cm (p< 0.0001), at the end of the study period (week 36). Systolic and diastolic blood pressure showed reductions after the two first weeks, which were maintained up to the end of the study. A clear shift to the left in FRS distribution curve occurred at the end of the study, compared to baseline, indicating a reduction in coronary risk. Over all patients at risk, 49.2% moved to a lower risk category. A weight loss > 5% occurred in 64.6% of all patients, associated with improvement in glucose metabolism. Among those with abnormal glucose metabolism, 38 out 53 patients (71.7%) improved their glucose tolerance (p< 0.0005). In conclusion, long-term orlistat therapy helps to reduce and maintain a lower body weight, decreasing risk of coronary disease and improving glucose metabolism, thus protecting against type 2 diabetes.
publishDate 2006
dc.date.none.fl_str_mv 2006-04-01
2015-06-14T13:32:05Z
2015-06-14T13:32:05Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S0004-27302006000200023
Arquivos Brasileiros de Endocrinologia & Metabologia. Sociedade Brasileira de Endocrinologia e Metabologia, v. 50, n. 2, p. 368-376, 2006.
10.1590/S0004-27302006000200023
S0004-27302006000200023.pdf
0004-2730
S0004-27302006000200023
http://repositorio.unifesp.br/handle/11600/3047
url http://dx.doi.org/10.1590/S0004-27302006000200023
http://repositorio.unifesp.br/handle/11600/3047
identifier_str_mv Arquivos Brasileiros de Endocrinologia & Metabologia. Sociedade Brasileira de Endocrinologia e Metabologia, v. 50, n. 2, p. 368-376, 2006.
10.1590/S0004-27302006000200023
S0004-27302006000200023.pdf
0004-2730
S0004-27302006000200023
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Arquivos Brasileiros de Endocrinologia & Metabologia
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 368-376
application/pdf
dc.publisher.none.fl_str_mv Sociedade Brasileira de Endocrinologia e Metabologia
publisher.none.fl_str_mv Sociedade Brasileira de Endocrinologia e Metabologia
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268286579245056